Literature DB >> 21030339

Erythema nodosum: etiological factors and relapses in a retrospective cohort study.

Anastasia Papagrigoraki1, Paolo Gisondi, Paolo Rosina, Manuela Cannone, Giampiero Girolomoni.   

Abstract

Erythema nodosum (EN) is a septal panniculitis which may be associated with a wide variety of factors and disorders. In some patients it is recurrent, but few studies have considered recurrent EN. Our aim was to describe the causes of and diseases associated with EN and relapsing EN. Patients diagnosed with EN from 1997 to 2007 were included. EN was defined as post-infective, based on temporal, clinical, laboratory and microbiological criteria. Diagnosis of drug-induced EN was based on a temporal correlation, on the relapse of EN after drug re-introduction and on the absence of relapsing EN with a continuous treatment with the imputed drug. When the above criteria were excluded and EN was not associated with an underlying systemic disease or pregnancy, it was considered idiopathic.124 patients (mean age 39.5 years; median 37 years; range 4-90 years) were visited and re-evaluated after one to ten years (mean ± SD follow up time 5 ± 4 years). In 73 (58.8%) patients an aetiology of the first manifestation of EN was attributed to infections (25.8% of the total number; 32% of those with an attributed aetiology), drugs (mostly sex hormones; 15.3%; 26%), systemic diseases (11.2%; 19.2%) and pregnancy (6.5%; 10.9%). EN relapsed in 33 (26.6%) patients and was mostly attributed to infections and drugs. Factors responsible for the first manifestation of EN frequently differed from those causing relapses in the same patients, with the exception of drug-induced EN. We conclude that drug-induced EN can recur after re-exposure to the same drug, and the recurrence can be predicted.

Entities:  

Mesh:

Year:  2010        PMID: 21030339     DOI: 10.1684/ejd.2010.1116

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  7 in total

Review 1.  Erythema nodosum.

Authors:  Alexander K C Leung; Kin Fon Leong; Joseph M Lam
Journal:  World J Pediatr       Date:  2018-09-29       Impact factor: 2.764

2.  Clinical Characteristics of Patients with Erythema Nodosum and Risk of Relapse - a 17-Year Study.

Authors:  Petros Ioannou; Angeliki M Andrianaki; Dimitra Dimopoulou; Sabine Kruger-Krasagakis; Dimitra Koumaki; Diamantis P Kofteridis; George Samonis; Konstantinos Krasagakis
Journal:  Maedica (Bucur)       Date:  2022-06

3.  Mycobacterium tuberculosis infection is associated with the development of erythema nodosum and nodular vasculitis.

Authors:  Sheng'an Chen; Jiazhen Chen; Lianjun Chen; Qiao'an Zhang; Xiaoqun Luo; Wenhong Zhang
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

4.  Erythema nodosum migrans successfully treated with indomethacin: A rare entity.

Authors:  Fatemeh Mokhtari; Bahareh Abtahi-Naeini; Mohsen Pourazizi
Journal:  Adv Biomed Res       Date:  2014-12-31

5.  Erythema nodosum: what should we consider about it?

Authors:  Farhang Babamahmoudi; Arghavan Amuzgar; Tahoora Mousavi; Lotfollah Davoodi
Journal:  Caspian J Intern Med       Date:  2016

6.  Clinicopathological Characteristics Related to Etiologies of Erythema Nodosum: A 10-Year Retrospective Study.

Authors:  Preeyachat Limtong; Poonkiat Suchonwanit; Kumutnart Chanprapaph; Suthinee Rutnin
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-30

7.  Erythema nodosum as a result of estrogen patch therapy for prostate cancer: a case report.

Authors:  Christopher Coyle; Stephen Mangar; Paul Abel; Ruth E Langley
Journal:  J Med Case Rep       Date:  2015-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.